Controlling the costs of prescription medications for patients with chronic illnesses is at the forefront of almost every stakeholder's agenda in healthcare. Increasingly, efforts are being made to incentivize providers to engage with patients in financially responsible decision making.
Controlling the costs of prescription medications for patients with chronic illnesses is at the forefront of almost every stakeholder’s agenda in healthcare. Increasingly, efforts are being made to incentivize providers to engage with patients in financially responsible decision making.
WellPoint, one of the largest insurance companies in the United States, said it would offer oncologists $350 per month for each patient that was prescribed one of the company’s recommended treatment regimens. The program is intended to standardize care delivery methods by providing treatment regimens which reduce wasteful spending and offer patients maximum health benefits.
Although such programs remain controversial among some practitioners in the oncology community, most recognize that large efforts are needed to control the rising costs of cancer treatment. Last year, the United States spent $37 billion on cancer drugs, and newer varieties can cost up to $100,000 for 1 round of treatment.
“Oncologist reimbursement at the moment is a broken system,” said Richard Schilsky, MD, FASCO, chief medical officer of the American Society of Clinical Oncology.
A recent study in The American Journal of Managed Care also found that financial stress can keep many patients from getting treatment or adhering to their medications. In particular, authors Didem Minbay Bernard, PhD, Patrik Johansson, MD, MPH, and Zhengyi Fang, MS, focused on patients with hypertension. They found that it is important for providers to recognize that their patients’ financial burdens can impact their treatment outcomes.
“Hypertension represents the most common reason for office visits to primary care physicians. However, recent studies show that 80% of physicians are unaware of medication costs and also misunderstand the complexities of health coverage,” the authors said in an official release. They add that health plans can adopt measures which would reduce of out-of-pocket costs for patients where there is strong evidence that treatment works for chronic illnesses such as hypertension.
Around the Web
Insurers Push to Rein In Spending on Cancer Care [The Wall Street Journal]
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen